Myriad Genetics Price Target Cut to $6.00/Share From $22.00 by Wells Fargo
A Quick Look at Today's Ratings for Myriad Genetics(MYGN.US), With a Forecast Between $10 to $18
Hold Rating Maintained for Myriad Genetics Amid Revenue Cuts and Strategic Uncertainty
Myriad Genetics Price Target Cut to $8.00/Share From $14.00 by Goldman Sachs
Myriad Genetics Analyst Ratings
UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating
Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22
Myriad Genetics (MYGN) Receives a Buy From Piper Sandler
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $8
Myriad Genetics Faces Revenue Declines and Strategic Challenges: Hold Rating Maintained
Craig-Hallum Maintains Myriad Genetics(MYGN.US) With Buy Rating
Leerink Partners Maintains Myriad Genetics(MYGN.US) With Hold Rating
Myriad Genetics Price Target Cut to $14.00/Share From $18.00 by Goldman Sachs
Myriad Genetics Analyst Ratings
Goldman Sachs Maintains Myriad Genetics(MYGN.US) With Buy Rating, Cuts Target Price to $14
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $11
Myriad Genetics Cut to Neutral From Buy by Guggenheim
Guggenheim Downgrades Myriad Genetics(MYGN.US) to Hold Rating
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Cuts Target Price to $20
Myriad Genetics Analyst Ratings